Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Deloitte
Accenture
McKinsey
Johnson and Johnson
US Department of Justice
Citi
Harvard Business School

Generated: June 20, 2018

DrugPatentWatch Database Preview

LAMISIL Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

Drug patent expirations by year for LAMISIL
Pharmacology for LAMISIL
Ingredient-typeAllylamine
Drug ClassAllylamine Antifungal
Synonyms for LAMISIL
((E)-6,6-Dimethyl-hept-2-en-4-ynyl)-methyl-naphthalen-1-ylmethyl-amine
(2E)-N,6,6-trimethyl-N-(1-naphthylmethyl)-2-hepten-4-yn-1-amine
(2E)-N,6,6-trimethyl-N-(1-naphthylmethyl)hept-2-en-4-yn-1-amine
(2E)-N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine
(2E)-N,6,6-Trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine (HCl)
(6,6-Dimethyl-hept-2-en-4-ynyl)-methyl-naphthalen-1-ylmethyl-amine
(6,6-Dimethyl-hept-2-en-4-ynyl)-methyl-naphthalen-1-ylmethyl-amine(Terbinafine)
(6,6-dimethylhept-2-en-4-yn-1-yl)methyl(1-naphthylmethyl)amine hydrochloride
(E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalene methanamine
(E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethylamine
(E)-N-(6,6-dimethyl-2-heptenynyl)-N-methyl-1-naphthalenementhamin hydrochloride
(E)-N-METHYL-N-(1-NAPHTHYLMETHYL)-6,6-DIMETHYL-HEPT-2-EN-4-YNYL-1-AMINE
(E)-N,6,6-trimethyl-N-(1-naphthalenylmethyl)-1-hept-2-en-4-ynamine
(E)-N,6,6-trimethyl-N-(1-naphthylmethyl)hept-2-en-4-yn-1-amine
(E)-N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine
[(2E)-6,6-dimethylhept-2-en-4-yn-1-yl](methyl)[(naphthalen-1-yl)methyl]amine
[(E)-6,6-dimethyl-hept-2-en-4-ynyl]-methyl-(naphthalen-1-yl-methyl)-amine
1-NAPHTHALENEMETHANAMINE, N-(6,6-DIMETHYL-2-HEPTEN-4-YNYL)-N-METHYL-, (E)-
161T716
1N,6,6-trimethyl-1N-(1-naphthylmethyl)-(E)-2-hepten-4-yn-1-amine
91161-71-6
A843743
AB0007727
AB00698510_12
AB00698510_13
AB00698510_14
AB00698510-07
AB00698510-09
AB00698510-10
AB00698510-11
AB05470
AB2000250
AC-8561
AC1LU7MZ
AK307954
AKOS001451917
ALBB-027269
AN-1287
AT-6016
BBL010959
BDBM50018518
BIDD:GT0825
Bramazil
BRN 4256376
C08079
CAS-91161-71-6
CCG-221253
CHEBI:9448
CHEBI:94705
CHEMBL822
Corbinal
CS-1944
D01AYJ
D02375
DB00857
DOMXUEMWDBAQBQ-WEVVVXLNSA-N
DR001103
DSSTox_CID_3640
DSSTox_GSID_23640
DSSTox_RID_77123
DTXSID2023640
erbinafine hydrochloride
G7RIW8S0XP
GS-3099
HMS2089B20
HY-17395A
K662
KB-50552
Lamasil
Lamasil (TN)
Lamisil (TN)
Lamisil AT
Lamisil Tablet
Lamisil, Terbinex, Corbinal, Zabel, Terbinafine
Lamisil;Terbinex;Corbinal;Zabel
LP120642
LS-94722
MFCD00242672
MLS006011885
MolPort-002-507-761
MolPort-004-637-919
N-[(2E)-6,6-dimethyl-2-hepten-4-yn-1-yl]-N-methyl-1-naphthalenemethanamine
N,6,6-Trimethyl-N-(1-naphthylmethyl)-2-heptene-4-yne-1-amine
N,6,6-trimethyl-N-(1-naphthylmethyl)hept-2-en-4-yn-1-amine hydrochloride
N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine
NCGC00159346-02
NCGC00159346-03
NCGC00159346-04
NCGC00188975-01
s1725
SBI-0206829.P001
SC-12217
SCHEMBL36794
SCHEMBL37843
SF 86-327
SF-86-327
SF-86327
SMR004703509
STK802069
STOCK5S-43972
TerbiFoam
Terbina
terbinafin
Terbinafina
terbinafine
Terbinafine (Lamisil, Terbinex)
Terbinafine (USAN/INN)
Terbinafine [USAN:BAN:INN]
Terbinafine [USAN:INN:BAN]
Terbinafine, SF-86-327, Lamisil, TBNF
Terbinafinehydrochloride
Terbinafinum
Terbinex
terbinol
Terbisil (TN)
Ternbinafine HCl
Tox21_111591
Tox21_111591_1
TX-012572
UNII-G7RIW8S0XP
Zabel
Zabel (TN)
ZINC1530981

US Patents and Regulatory Information for LAMISIL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline LAMISIL terbinafine hydrochloride CREAM;TOPICAL 020980-001 Mar 9, 1999 OTC Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Novartis LAMISIL terbinafine hydrochloride TABLET;ORAL 020539-001 May 10, 1996 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Novartis LAMISIL terbinafine hydrochloride GRANULE;ORAL 022071-001 Sep 28, 2007 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline Cons LAMISIL AT terbinafine GEL;TOPICAL 021958-001 Jul 24, 2006 OTC Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for LAMISIL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline Cons LAMISIL terbinafine GEL;TOPICAL 020846-001 Apr 29, 1998 ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline Cons LAMISIL terbinafine GEL;TOPICAL 020846-001 Apr 29, 1998 ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline Cons LAMISIL terbinafine GEL;TOPICAL 020846-001 Apr 29, 1998 ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline LAMISIL terbinafine hydrochloride CREAM;TOPICAL 020980-001 Mar 9, 1999 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Queensland Health
Healthtrust
Medtronic
Farmers Insurance
UBS
Cerilliant
Moodys
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.